207_Combined course Presentations

EORTC 62931

• Results – No difference in 5-year OS (chemo 66·5%, control 67·8%)

• Conclusions “Future studies should focus on patients with larger, grade III, and extremity sarcomas”

Woll PJ, et al. Lancet Oncol. 2012;13(10):1045-54